Global Brugada Syndrome Market

Brugada Syndrome Market Size, Share, Growth Analysis, By Diagnostic Tools(Genetic Testing, Electrocardiogram (ECG), Electrophysiological Studies (EPS), Implantable Cardioverter Defibrillators (ICDs).), By Treatment Modalities (Medications (Sodium Channel Blockers), Implantable Cardioverter Defibrillator (ICD) Therapy, and Catheter Ablation), By End-Users(Hospitals, Specialty Clinics, and Ambulatory Surgical Center), By Region - Industry Forecast 2024-2031

Report ID: SQMIG35D2229 | Region: Global | Published Date: March, 2024
Pages: 158 | Tables: 91 | Figures: 76

Brugada Syndrome Market News

  • August 2023: Dr. Charles Antzelevitch and his team at the Lankenau Institute for Medical Research (LIMR) have collaborated with the Mayo Clinic for four years to combat rare but fatal cardiac conditions. This summer, a groundbreaking discovery revealed a potential solution in traditional Chinese medicine derived from plants like safflower.
  • November 2023: Quinidine has been reported to be effective in treating patients with BrS,10,11 but unfortunately the drug is not easy to tolerate over a lifetime because of its side effects and withdrawal is reported in about a one-third of patients.
  • August 2023: The demand for heart transplants has surged due to increased heart failure cases, leading to a shortage of eligible organs. As of March 2022, the National Database of the Health Resources and Services Administration reported 4150 candidates on the heart transplant waiting list in the United States. Globally, disparities exist, with Australia having just over 500 volunteers in 2022 for 1,760 individuals awaiting heart transplants. The Transplant Activity Report 2022 reveals a 120% increase in the number of people on heart transplant waiting lists since 2010.
$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Brugada Syndrome Market size was valued at USD 1.54 billion in 2022 and is poised to grow from USD 1.45 billion in 2023 to USD 2.26 billion by 2031, growing at a CAGR of 5.7% in the forecast period (2024-2032).

The competitive environment of the Brugada Syndrome market is characterized by the active participation of pharmaceutical companies, diagnostic laboratories, medical device manufacturers, and research institutions. Key players in this market engage in strategic initiatives such as research and development collaborations, partnerships, and acquisitions to advance diagnostic and therapeutic technologies for Brugada syndrome. The competitive dynamics are influenced by the pursuit of innovative genetic testing methods, AI integration in diagnostic tools, and the development of novel treatment modalities such as catheter ablation. 'Abbott Laboratories', 'Medtronic plc', 'Boston Scientific Corporation', 'Biotronik SE & Co. KG', 'St. Jude Medical, Inc. (Acquired by Abbott)', 'Microport Scientific Corporation', 'GE Healthcare', 'Siemens Healthineers', 'AstraZeneca plc', 'Boehringer Ingelheim Pharmaceuticals, Inc.', 'Bayer AG', 'Pfizer Inc.', 'Novartis International AG', 'Roche Diagnostics', 'Philips Healthcare', 'Johnson & Johnson', 'Genetron Health (Beijing) Co., Ltd.', 'MyoKardia, Inc. (Acquired by Bristol Myers Squibb)', 'Invitae Corporation', 'Illumina, Inc.'

The increased awareness and understanding of Brugada syndrome among healthcare professionals and the general population serve as a fundamental driver. This heightened awareness facilitates early diagnosis and intervention, positively impacting patient outcomes.

Rising Emphasis on Genetic Testing: The growing emphasis on genetic testing as a trend, driven by the increasing recognition of the genetic basis of Brugada syndrome. Advances in genomic technologies are enabling more accurate and accessible genetic analyses for identifying mutations associated with the syndrome. Additionally, the integration of artificial intelligence (AI) in electrocardiogram (ECG) analysis is gaining prominence, enhancing the precision of diagnosis through automated detection of subtle abnormalities. 

North America, particularly the United States, boasts advanced healthcare infrastructure and a robust research ecosystem, facilitating widespread adoption of advanced diagnostic tools and treatment modalities for Brugada Syndrome. The region demonstrates high awareness among healthcare professionals and the public regarding cardiac disorders. This awareness, coupled with substantial research activities, contributes to the dominance of North America in the Brugada Syndrome market.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

Click here right-arrow
logo-images

Related Reports

Dravet Syndrome Market
Buy Now GET FREE SAMPLE
Aicardi Syndrome Market
Buy Now GET FREE SAMPLE
Malabsorption Syndrome Market
Buy Now GET FREE SAMPLE
Dry Eye Syndrome Treatment Market
Buy Now GET FREE SAMPLE
Leukapheresis Market
Buy Now GET FREE SAMPLE
Dry Eye Disease Market
Buy Now GET FREE SAMPLE
Zoonotic Disease Treatment Market
Buy Now GET FREE SAMPLE
Spirulina Market
Buy Now GET FREE SAMPLE

Feedback From Our Clients

Global Brugada Syndrome Market

Report ID: SQMIG35D2229

$5,300
BUY NOW GET FREE SAMPLE